Ambrx Biopharma Inc.
NYSE:AMAM

13.68 USD +0.07 USD ( +0.51% )

Ambrx Biopharma Inc. (NYSE:AMAM)

Add AMAM to Watchlist

Summary

Business Profile
Ambrx Biopharma Inc.

Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. Ambrx Biopharma Inc. has collaborations with various pharmaceutical companies, which include Bristol Myers Squibb Company; AbbVie Inc.; Astellas Pharma Inc.; and Elanco Animal Health. The company was founded in 2003 and is based in La Jolla, California. [ Read More ]

Country

United States of America

Industry

Biotechnology

Market Cap

515M USD

Enterprise Value

-

Dividend Yield

0%

Buyback Yield

0%

Investment Score
Ambrx Biopharma Inc.

No Valuation Score Available

There isn't enough data to calculate the valuation score.

No Profitability Score Available

There isn't enough data to calculate the profitability score.

No Solvency Score Available

There isn't enough data to calculate the solvency score.

Competitors

Competitors Valuation Chart
Ambrx Biopharma Inc. Competitors

Competitors Valuation Table
Ambrx Biopharma Inc. Competitors

Shareholder Return

Stock Performance
AMAM Price Statistics

AMAM Market
1 Week +7% +1%
6 Months -20% +8%
1 Year -20% +31%
3 Years -20% +65%

Stock Price
AMAM Price Chart

1M
6M
1Y
3Y
5Y